Abstract
Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.
| Original language | English |
|---|---|
| Pages (from-to) | 309-313 |
| Number of pages | 5 |
| Journal | Bone Marrow Transplantation |
| Volume | 25 |
| Issue number | 3 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Autologous peripheral blood progenitor cell transplantation
- Carmustine
- Pulmonary toxicity
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. / Alessandrino, E. P.; Bernasconi, P.; Colombo, A.; Caldera, D.; Martinelli, G.; Vitulo, P.; Malcovati, L.; Nascimbene, C.; Varettoni, M.; Volpini, E.; Klersy, C.; Bernasconi, C.
In: Bone Marrow Transplantation, Vol. 25, No. 3, 2000, p. 309-313.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies
AU - Alessandrino, E. P.
AU - Bernasconi, P.
AU - Colombo, A.
AU - Caldera, D.
AU - Martinelli, G.
AU - Vitulo, P.
AU - Malcovati, L.
AU - Nascimbene, C.
AU - Varettoni, M.
AU - Volpini, E.
AU - Klersy, C.
AU - Bernasconi, C.
PY - 2000
Y1 - 2000
N2 - Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.
AB - Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.
KW - Autologous peripheral blood progenitor cell transplantation
KW - Carmustine
KW - Pulmonary toxicity
UR - http://www.scopus.com/inward/record.url?scp=19244370150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19244370150&partnerID=8YFLogxK
M3 - Article
C2 - 10673703
AN - SCOPUS:19244370150
VL - 25
SP - 309
EP - 313
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 3
ER -